INNOVATION
R&D
PIPELINE
OUR RESEARCH AREA
EXPLORING DIVERSE PROBIOTICS RESEARCH
Our research area encompasses a diverse range of scientific endeavors aimed at advancing human health through microbiome science, probiotics, and microbiological engineering. At Cell Biotech, we are committed to pioneering breakthroughs in healthcare through innovative research and development. Our team of experts collaborates across various fields to explore the potential of probiotics and microbiome science in addressing critical health challenges.
ANTI-CANCER | in-vitro, in-vivo | Colorectal cancer treatment (PP-P8) |
ANTIMICROBIAL ACTIVITY | in-vivo | Prevention of S.typhimurium |
ANTIMICROBIAL ACTIVITY | in-vivo | Food-borne pathogens |
ANTIMICROBIAL ACTIVITY | in-vivo | Prevention of E.coli |
ANTIMICROBIAL ACTIVITY | in-vivo | Prevention of Salmonella |
ANTIMICROBIAL ACTIVITY | in-vivo | Prevention of C. difficile |
BABY HEALTH | Clinical Trial
| Indigestible oligosaccharide utilization (HMO) |
BABY HEALTH | Clinical Trial
| Lactose intolerance |
BABY HEALTH | Clinical Trial
| Acute rotaviral diarrhea, |
BIOCONVERSION | in-vitro, in-vivo | Protein Absorption |
BIOCONVERSION | in-vitro, in-vivo | Bioconversion of
multivitamin and minerals |
BIOCONVERSION | in-vitro, in-vivo | Bioconversion of Ginsenosides and Rutin |
BONE HEALTH | in-vivo | Osteoporosis |
BONE HEALTH | in-vivo | Rheumatoid arthritis |
GENOME SEQUENCING | Genomic Research | Whole genome sequencing of probiotic strain |
GENOME SEQUENCING | Genomic Research | Comparative genomic analyses |
GUT HEALTH | Clinical Trial
| IBD (Inflammatory Bowl Disease) |
GUT HEALTH | Clinical Trial
| Acute diarrhea |
GUT HEALTH | Clinical Trial
| IBS (Irritable Bowel Syndrome) |
GUT HEALTH | in-vivo | Relief of gastrointestinal
side effects induced by
medicine (NSAIDs) |
ANTI-COLORECTAL CANCER TREATMENT
A PIONEERING ADVANCEMENT IN MICROBIOME-BASED THERAPEUTICS
PP-P8 Protein &
Drug Delivery System (DDS)
Developed from our patented strains, 'CBT-LR5 (Lactobacillus Rhamnosus CBT-LR5, KCTC 12202BP)' and 'CBT-SL4 (Pediococcus Pentosaceus CBT-SL4, KCTC 10297BP)', PP-P8 boasts a unique formulation capable of producing the anti-cancer protein 'P8' in significant quantities. Utilizing cutting-edge genetic engineering, P8 targets and inhibits the proliferation of colorectal cancer cells by binding to the GSK3β protein, a key regulator of cell cycle progression.
Furthermore, our research has demonstrated that PP-P8 effectively restores gut microbiome balance, a critical factor in colorectal cancer treatment, as evidenced by its publication in the esteemed international journal 'Microbiome'.
Phase I Clinical Trial
The clinical trial for the new colon cancer drug PP-P8 is being conducted in collaboration with Seoul National University Hospital. A total of 32 patients with metastatic colon cancer (rectal cancer) are being evaluated for PP-P8's tolerability, safety, and efficacy.
In the dose escalation phase (Part 1), the dose is gradually increased to assess safety, while in the dose expansion phase (Part 2), the appropriate dose is selected to explore efficacy.
With these groundbreaking findings, Cell Biotech is committed to expanding our drug development pipeline to address various medical needs, including diabetes and gastric cancer, using our probiotic drug delivery system and DNA recombinant probiotics.With the convenience of an oral probiotic drug delivery system, PP-P8 is poised to revolutionize cancer treatment by offering heightened efficacy while minimizing side effects.